- Home
- CDNA vs BDN Comparison
CDNA vs BDN Comparison
Compare CDNA & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- BDN
- Stock Information
- Founded
- CDNA 1998
- BDN 1986
- Country
- CDNA United States
- BDN United States
- Employees
- CDNA N/A
- BDN N/A
- Industry
- CDNA Medical Specialities
- BDN Real Estate Investment Trusts
- Sector
- CDNA Health Care
- BDN Real Estate
- Exchange
- CDNA Nasdaq
- BDN Nasdaq
- Market Cap
- CDNA 1.1B
- BDN 951.4M
- IPO Year
- CDNA 2014
- BDN N/A
- Fundamental
- Price
- CDNA $23.34
- BDN $5.56
- Analyst Decision
- CDNA Buy
- BDN Buy
- Analyst Count
- CDNA 8
- BDN 3
- Target Price
- CDNA $27.17
- BDN $5.83
- AVG Volume (30 Days)
- CDNA 642.2K
- BDN 2.0M
- Earning Date
- CDNA 02-26-2025
- BDN 02-04-2025
- Dividend Yield
- CDNA N/A
- BDN 10.69%
- EPS Growth
- CDNA N/A
- BDN N/A
- EPS
- CDNA N/A
- BDN N/A
- Revenue
- CDNA $312,775,000.00
- BDN $306,926,000.00
- Revenue This Year
- CDNA $19.85
- BDN N/A
- Revenue Next Year
- CDNA $11.34
- BDN $2.29
- P/E Ratio
- CDNA N/A
- BDN N/A
- Revenue Growth
- CDNA 5.26
- BDN N/A
- 52 Week Low
- CDNA $7.42
- BDN $3.85
- 52 Week High
- CDNA $34.84
- BDN $6.54
- Technical
- Relative Strength Index (RSI)
- CDNA 56.42
- BDN 49.73
- Support Level
- CDNA $20.35
- BDN $5.39
- Resistance Level
- CDNA $21.68
- BDN $5.76
- Average True Range (ATR)
- CDNA 1.10
- BDN 0.20
- MACD
- CDNA 0.19
- BDN 0.00
- Stochastic Oscillator
- CDNA 99.09
- BDN 48.48
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.